Equibles does not estimate personal net worth.
Get an email with a short summary when Arrowhead Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ARWR alertsChristopher Anzalone is recorded as CEO and Board Member at Arrowhead Pharmaceuticals, Inc. (ARWR). The newest filing on record that lists Christopher Anzalone as CEO and Board Member at Arrowhead Pharmaceuticals, Inc. (ARWR) is dated January 27, 2026. The proxy statement of Arrowhead Pharmaceuticals, Inc. reports total compensation of $12,423,473 for Christopher Anzalone in fiscal 2024, including a base salary of $951,012. Disclosed compensation is on record for 5 fiscal years. Christopher Anzalone has spoken on 18 earnings calls and 2 other investor events across 1 company, most recently for Arrowhead Pharmaceuticals, Inc. on June 10, 2026. Arrowhead Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arrowhead Pharmaceuticals, Inc. includes Daniel Apel (CFO), Patrick O'Brien (COO), Patrick O’Brien (COO and General Counsel) and 6 others.
“And thanks, everyone, at Goldman, for having us today. So, 2026 feels like another big year for Arrowhead.”
“R&D is great, but unless you can bring these medicines to patients, then there's no point in that, right? So we've had a huge – it's been a big transition for us to start to build out this commercial force, and it's been successful so far.”
“Before we begin, I'd like to announce that this will be Bruce Given's final earnings call. He's been a valuable member of the Arrowhead Pharmaceuticals team for almost fifteen years.”
“Before discussing the progress we've made over the past quarter, I'd like to address questions surrounding our partnership with Sarepta Therapeutics. Sarepta has recently experienced high-profile setbacks in products and programs that are unrelated to those licensed from Arrowhead.”
“Before I start, I want to say thank you to Ken and wish him the best in his retirement. Ken has been a valuable member of the Arrowhead team and he retires at a time of great financial strength for the company.”
Start not stated–present
Last confirmed January 27, 2026
Start not stated–present
Last confirmed January 27, 2026
Biotechnology · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Arrowhead Pharmaceuticals, Inc. (ARWR) | President and Chief Executive Officer | $951,012 | $12,423,473 |
| 2023 | Arrowhead Pharmaceuticals, Inc. (ARWR) | President and Chief Executive Officer | $902,522 | $9,918,093 |
| 2022 | Arrowhead Pharmaceuticals, Inc. (ARWR) | President and Chief Executive Officer | $863,417 | $12,031,969 |
| 2021 | Arrowhead Pharmaceuticals, Inc. (ARWR) | President and Chief Executive Officer | $837,031 | $24,703,855 |
| 2020 | Arrowhead Pharmaceuticals, Inc. (ARWR) | President and Chief Executive Officer | $785,625 | $14,294,517 |
